Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Down 93.6% in July

Universe Pharmaceuticals INC (NASDAQ:UPC) was the target of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 15,446 shares, a drop of 93.6% from the June 30th total of 239,483 shares. Currently, 6.4% of the company’s stock are short sold. Based on an average daily trading volume, of 748,993 shares, the days-to-cover ratio is presently 0.0 days.

Universe Pharmaceuticals Stock Down 10.6%

NASDAQ:UPC traded down $0.40 during trading hours on Friday, reaching $3.39. 43,299 shares of the company’s stock were exchanged, compared to its average volume of 4,162,160. The company has a 50-day moving average of $3.98 and a 200 day moving average of $3.50. Universe Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $17.96.

Analyst Ratings Changes

Separately, Weiss Ratings cut Universe Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Universe Pharmaceuticals currently has a consensus rating of “Sell”.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.